This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    04/04/16

    CHMP recommends Trevicta (paliperidone palmitate a 3-monthly injection) to treat schizophrenia.-Janssen Cilag

    Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    01/06/16

    EMA approves Trevicta (paliperidone palmitate a three monthly injection) for the maintenance treatment of schizophrenia.- Janssen Cilag

    Janssen-Cilag International NV announced that the European Commission (EC) has approved the use of Trevicta (paliperidone palmitate a three monthly...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    06/08/24

    FDA approves Erzofri (paliperidone palmitate) for the treatment of schizophrenia and schizoaffective disorder

    The FDA has approved Luye Pharma’s paliperidone palmitate (Erzofri) extended-release injectable suspension for the treatment of schizophrenia in adults and schizoaffective disorder in adults as monotherapy, as well as an adjunct to mood stabilizers or antidepressants

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    15/04/15

    Data on Invega Sustenna (paliperidone palmitate) in Schizophrenia published in JCP-Janssen Pharmaceuticals

    A study published in The Journal of Clinical Psychiatry shows that long-acting Invega Sustenna (paliperidone palmitate), from Janssen Pharmaceuticals, was...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    21/11/14

    Janssen files NDA at FDA for three months formulation of Invega Sustenna for Schizophrenia

    Janssen Research & Development, LLC (Janssen) has announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    15/11/14

    FDA approves Invega Sustenna for Schizoaffective Disorder-Janssen Pharma

    The FDA approved the supplemental New Drug Applications (sNDAs) for the once-monthly atypical long-acting antipsychotic Invega Sustenna (paliperidone palmitate), from...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/11/24

    FDA approves Invega Hayfera, for adults with schizophrenia.

    The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    29/03/15

    Phase III results with Invega Sustenna/Xeplion (paliperidone palmitate) in Schizophrenia published in JAMA- Janssen

    Three-month treatment with Invega Sustenna/Xeplion (paliperidone palmitate), from Janssen Pharmaceuticals, significantly delayed time to relapse compared to placebo in patients...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/05/15

    FDA approves Invega Trinza (three month paliperidone palmitate) to treat schizophrenia-Janssen Pharma

    Janssen Pharmaceuticals, Inc. announced that the FDA approved under priority review the New Drug Application (NDA) for the three-month long-acting...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    05/05/14

    Positive results from study of Invega Sustenna for Schizophrenia-Janssen

    Janssen Pharmaceuticals has announced results of its landmark PRIDE trial, a prospective, randomized clinical trial to compare Invega Sustenna/Xeplion (paliperidone...

    See more